Allecra Therapeutics, led by CEO Nicholas Benedict, is a biopharmaceutical company based in Lörrach, Germany and Saint‑Louis, France focused on treatments for multi drug‑resistant Gram‑negative bacterial infections. Its lead program, AAI202, is a combination of a β‑lactam antibiotic and a proprietary extended‑spectrum β‑lactamase inhibitor intended as broad‑spectrum antibacterial therapy for hospitalized patients with Gram‑negative infections. The company is advancing AAI202 toward clinical development to address infections proven or suspected to express certain resistance mechanisms, particularly ESBLs. Allecra closed a Series B financing to fund the next stage of development. The company intends to use the proceeds for Phase 2 development of AAI202. No operating metrics were disclosed in the article. Allecra Therapeutics is an antibiotics startup formed this year to develop a pair of antibiotics against multi‑drug‑resistant gram‑negative bacteria. The company raised a €15 million Series A to fund clinical development of those programs. Allecra was created through a partnership led by CEO Nicholas Benedict and India's Orchid Chemicals & Pharmaceuticals. Lead backers include Forbion Capital Partners and Edmond de Rothschild Investment Partners, and EMBL Ventures has also invested. The company operates in Lorrach, Germany and Saint Louis, France. Founders and investors cite retreating big‑pharma R&D as creating an urgent need for new antibiotic options and position Allecra to address that gap.

Total raised

$44M

Funding rounds

2

Latest round

Series B

Latest activity

Jun 2016